Sign Out
Psoriatic arthritis
Adult: For the treatment of active and progressive cases in patients who had an inadequate response to DMARDs: 25 mg twice weekly at intervals of 3-4 days or 50 mg once weekly. Discontinue treatment if no adequate response after 12 weeks.
Child: In patients who have had an inadequate response to or who have proved intolerant of conventional therapy: ≥12 years 0.4 mg/kg twice weekly at intervals of 3-4 days. Max: 25 mg/dose. Alternatively, 0.8 mg/kg once weekly. Max: 50 mg/dose. Discontinue treatment if no adequate response after 4 months. Dosing recommendations may vary among countries (refer to specific product guidelines).
Child: In patients who have had an inadequate response to or who have proved intolerant of conventional therapy: ≥12 years 0.4 mg/kg twice weekly at intervals of 3-4 days. Max: 25 mg/dose. Alternatively, 0.8 mg/kg once weekly. Max: 50 mg/dose. Discontinue treatment if no adequate response after 4 months. Dosing recommendations may vary among countries (refer to specific product guidelines).
Subcutaneous
Ankylosing spondylitis, Non-radiographic axial spondyloarthritis
Adult: For active cases in patients who had an inadequate response to conventional therapy: 25 mg twice weekly at intervals of 3-4 days or 50 mg once weekly. Discontinue treatment if no adequate response after 12 weeks.
Subcutaneous
Rheumatoid arthritis
Adult: For moderate to severe active cases in patients who had an inadequate response to disease-modifying antirheumatic drugs (DMARDs): As monotherapy or in combination with methotrexate: 25 mg twice weekly at intervals of 3-4 days. Alternatively, 50 mg once weekly. Discontinue treatment if no adequate response after 6 months.
Subcutaneous
Enthesitis-related arthritis
Adult: For moderate to severe cases in patients who are intolerant to, failed to respond to, or have contraindications to other systemic therapy or phototherapy: 25 mg twice weekly or 50 mg once weekly. Alternatively, 50 mg twice weekly at intervals of 3-4 days for up to 12 weeks, if necessary, followed by 25 mg twice weekly or 50 mg once weekly. Continue therapy until remission is achieved, for up to 24 weeks. Discontinue treatment if no adequate response after 12 weeks.
Child: For chronic severe cases in patients who are inadequately controlled or intolerant to other systemic therapy or phototherapies: ≥6 years 0.8 mg/kg once weekly for up to 24 weeks. Max: 50 mg/dose. Discontinue treatment if no adequate response after 12 weeks.
Child: For chronic severe cases in patients who are inadequately controlled or intolerant to other systemic therapy or phototherapies: ≥6 years 0.8 mg/kg once weekly for up to 24 weeks. Max: 50 mg/dose. Discontinue treatment if no adequate response after 12 weeks.
Subcutaneous
Plaque psoriasis
Child: In patients who have had an inadequate response to or who have proved intolerant of conventional therapy: ≥2 years 0.4 mg/kg twice weekly at intervals of 3-4 days. Max: 25 mg/dose. Alternatively, 0.8 mg/kg once weekly. Max: 50 mg/dose. Discontinue treatment if no adequate response after 4 months.
Subcutaneous
Polyarticular juvenile idiopathic arthritis
Child: In patients who have had an inadequate response to or who have proved intolerant of conventional therapy: ≥12 years 0.4 mg/kg twice weekly at intervals of 3-4 days. Max: 25 mg/dose. Alternatively, 0.8 mg/kg once weekly. Max: 50 mg/dose. Discontinue treatment if no adequate response after 4 months. Treatment recommendations may vary among countries (refer to specific product guidelines).
